孟鲁司特联合转移因子治疗儿童支气管哮喘临床观察

Montelukast joint transfer factor Bronchial Asthma in Children Clinical observation

目的:观察孟鲁司特钠联合转移因子应用于临床治疗儿童哮喘的疗效。方法:将我院呼吸科130例轻中度哮喘患儿按照随机原则分成治疗组65例和对照组65例,对照组单独使用孟鲁司特钠咀嚼片治疗,对照组在治疗组基础上加用转移因子口服液治疗,两组均治疗180天后统计疗效。结果:治疗组和对照组的显效率分别为87.7%、55.38%,差异有显著性意义(P<0.05)。结论:孟鲁司特钠与转移因子联合用药比单独使用孟鲁司特钠应用于临床治疗儿童哮喘效果更佳,且不良反应轻微,安全性好。

Objective：To observe the montelukast factor transfer factor used in clinical treatment of children with asthma.Methods：The hospital respiratory department 130 patients with mild to moderate asthma according to randomly assigned to treatment group 65 cases and the control group,65 patients in the control group alone montelukast sodium chewable tablets in treatment and control group in the treatment group based on plus transfer factor on treatment,patients were treated for 180d after the statistical effect.Results：The treatment group and control group was effective rate was 87.7%,55.38%,the difference was significant（P 0.05）.Conclusion：Montelukast sodium and transfer factor in combination than alone montelukast sodium used in clinical treatment of children with asthma better effect,and adverse reactions were mild,safe and good.